Selected article for: "acute ards respiratory distress syndrome treat and lung injury"

Author: Tabassum, Neha; Zhang, Hua; Stebbing, Justin
Title: Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
  • Cord-id: yqfnvnq2
  • Document date: 2020_11_17
  • ID: yqfnvnq2
    Snippet: A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
    Document: A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

    Search related documents:
    Co phrase search for related documents